Key result
Sotatercept, macitentan/tadalafil, inhaled treprostinil, and remote PAP monitoring show promise in improving PH outcomes.
Why the study?
PAH is an underrecognized condition with high mortality, prompting this discussion of critical updates and newer therapies in the constantly evolving field.
Do novel therapies and remote hemodynamic monitoring improve clinical and hemodynamic outcomes in patients with pulmonary hypertension?
Do novel therapies and remote hemodynamic monitoring improve clinical and hemodynamic outcomes in patients with pulmonary hypertension?
This review highlights that novel targeted therapies and remote hemodynamic monitoring offer significant improvements in morbidity and hemodynamics for patients across various groups of pulmonary hypertension, though long-term safety and global accessibility remain challenges.
Promising PH advances should not yet change practice; leaves open long-term safety and access questions.
Pulmonary Arterial Hypertension (PAH) is an uncommon condition with high mortality. It is an underrecognized condition both in developing and developed countries, especially in developing countries, due to a lack of advanced healthcare facilities and resources for timely diagnosis. More than half of the individuals diagnosed with PAH live less than five years after diagnosis. In recent years, tremendous advancements have been made in diagnostic and therapeutic strategies for PAH patients. Phosphodiesterase 5 (PDE5) inhibitors, endothelin receptor antagonists, and prostacyclin inhibitors in various forms (oral, inhaled, intravenous, or subcutaneous) have been the cornerstone of medical treatment. Atrial septostomy, heart and lung transplant, balloon pulmonary angioplasty, and pulmonary thromboendarterectomy are existing therapeutic options currently available. There has been a continuous effort to introduce newer therapies to improve life expectancy and modify disease. Newer therapies have shown promising results but require future data to guarantee long-term safety and efficacy. We aim to discuss a few of these critical updates in the constantly evolving field of PAH.
No takes yet. Share an insight, caveat, or question.
Paudyal et al. (2025) conducted a review in Pulmonary Hypertension. Newer therapies (Sotatercept, Macitentan/Tadalafil, Inhaled Treprostinil, Remote PAP monitoring) was evaluated. Recent advancements in pulmonary hypertension therapies, including sotatercept, macitentan/tadalafil combination, inhaled treprostinil, and remote PAP monitoring, show promising results in improving patient outcomes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: